Business Context and Reporting Period
This Form 8-K Current Report was filed by Neogen Corporation on October 30, 2025. The filing primarily addresses the appointment of a new Senior Vice President and Chief Financial Officer (CFO) and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data provided relates to the executive compensation package for the new CFO:
- Base Salary: $600,000 annually.
- Target Annual Bonus: 80% of base salary ($480,000), with a potential range of 0% to 250% of target.
- Long-Term Incentive Target: $2,000,000 in equity value at grant.
- Sign-On Equity Grant: $2,250,000 (50% stock options, 50% performance share units).
- Sign-On Cash Award: $250,000 (subject to clawback if employment terminates within one year).
Material Changes
The material change reported is the appointment of Bryan Riggsbee as Senior Vice President and Chief Financial Officer, effective November 3, 2025. Mr. Riggsbee joins from bioMérieux, where he served as CFO for North America, and previously held CFO roles at Myriad Genetics, LabCorp, and GE. He will report directly to President and CEO Mike Nassif.
Outlook, Risks, and Contingencies
Management Commentary: The appointment is intended to strengthen the company's financial leadership. Mr. Riggsbee brings experience overseeing a $2 billion business and expanding international markets.
Contingencies and Risks:
- Clawback Provisions: The $250,000 sign-on cash award must be repaid if Mr. Riggsbee terminates employment within one year. Relocation benefits are subject to 100% repayment if he terminates within one year of relocating to Michigan, and 50% repayment if within two years.
- Employment Status: Employment is at-will and subject to customary pre-employment conditions, including background verification and execution of non-disclosure and non-competition agreements.
Investor Verification Checklist
- Verify the effective start date of November 3, 2025, and any potential interim financial leadership arrangements.
- Review the specific vesting schedules for the $2,250,000 sign-on equity grant (3-year ratable for options; performance-based for PSUs).
- Confirm the terms of the "Offer Letter" (Exhibit 10.1) for detailed performance metrics tied to the Incentive Compensation Plan and PSU Plan.
- Monitor future filings for the impact of this executive transition on the company's strategic financial direction.